John Ruvane Joins NextWorks as SVP Business Development
New York, NY, June 8, 2015. NextWorks, developer of the Content Capsule™ digital marketing platform, has named pharmaceutical and healthcare marketing veteran John Ruvane as Senior Vice President, Business Development. Ruvane will be based in New York.
“John brings extensive experience in healthcare and pharmaceutical marketing,” said Tim Bahr, NextWorks CEO. “His expertise and relationships will help us apply our content creation and delivery solutions to a wide range of healthcare marketing and communications challenges.”
Ruvane most recently served as Senior Vice President of Sales and Business Development at HealthPrize, a patient engagement platform. He has held senior leadership roles at Medimedia and inChord Communications/inVentiv Health. He began his career at Forest Laboratories (now Actavis). His experience spans professional, payer, and patient segments.
“I am very excited to join NextWorks and to help expand on the success the team has already achieved” said Ruvane. “The Content Capsule platform, combined with NextWork’s deep experience in healthcare content production, presents very innovative new ways to drive measurably higher rates of engagement with all healthcare stakeholders.”
Content Capsules are portable websites that can be embedded, monitored and simultaneously programed with new content anywhere a target audience spends time online. Capsules are responsive and optimized across mobile, tablet, and desktop. Major healthcare and consumer brands are using the Content Capsule platform to create highly sharable and measurable interactive experiences across owned, earned, shared and paid digital channels.
NextWorks is an innovative creative and technology company that helps brands tell stories by efficiently and effectively producing, packaging and distributing digital content. Our unique interactive solution, The Content Capsule, makes it easy to integrate complete brand experiences across all digital media channels.
Ad Right Top
June 2015 Focus: Top 100 Biotech & DTC